Título :	Fever after peripheral blood stem cell infusion in haploidentical transplantation with post-transplant cyclophosphamide
Tipo de documento :	documento electrónico
Autores :	Marcos Arango Barrientos, ; Juan Felipe Combariza Vallejo,
Fecha de publicación :	2017
Títulos uniformes :	Hematology/Oncology and Stem Cell Therapy
Idioma :	Inglés (eng)
Palabras clave :	Cyclophosphamide  fever  haploidentical hematopoietic stem cell transplantation  peripheral blood stem cell transplantation  prognosis
Resumen :	Objective/background: Noninfection-related fever can occur after peripheral blood stem cell infusion in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. The objective of this study was to analyze the incidence of fever and characterize some clinical features of affected patients. Methods: A retrospective case-series study with 40 patients who received haploidentical hematopoietic stem cell transplantation was carried out. Results Thirty-three patients (82.5%) developed fever; no baseline characteristic was associated with its development. Median time to fever onset was 25.5 h (range, 9.5–100 h) and median peak temperature was 39.0 °C (range, 38.1–40.5 °C). Not a single patient developed hemodynamic or respiratory compromise that required admission to the intensive care unit. Fever was not explained by infection in any case. Ninety-one percent of the febrile episodes resolved within 96 h of cyclophosphamide administration. No significant difference in overall survival, event-free survival, or graft versus host disease-free/relapse-free survival was found in the group of febrile individuals after peripheral blood stem cell infusion. Conclusion: Fever after peripheral blood stem cell infusion in this clinical setting was common; it usually subsides with cyclophosphamide administration. The development of fever was not associated with an adverse prognosis.
Mención de responsabilidad :	Marcos Arango, Juan F Combariza
Referencia :	Hematol Oncol Stem Cell Ther. 2017 Jun;10(2):79-84.
DOI (Digital Object Identifier) :	10.1016/j.hemonc.2017.03.001
PMID :	28390959
En línea :	https://linkinghub.elsevier.com/retrieve/pii/S1658-3876(17)30031-6
Enlace permanente :	https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis

Fever after peripheral blood stem cell infusion in haploidentical transplantation with post-transplant cyclophosphamide [documento electrónico] / Marcos Arango Barrientos, ; Juan Felipe Combariza Vallejo,  . - 2017.
Obra : Hematology/Oncology and Stem Cell Therapy

Idioma : Inglés (eng)

Palabras clave :	Cyclophosphamide  fever  haploidentical hematopoietic stem cell transplantation  peripheral blood stem cell transplantation  prognosis
Resumen :	Objective/background: Noninfection-related fever can occur after peripheral blood stem cell infusion in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. The objective of this study was to analyze the incidence of fever and characterize some clinical features of affected patients. Methods: A retrospective case-series study with 40 patients who received haploidentical hematopoietic stem cell transplantation was carried out. Results Thirty-three patients (82.5%) developed fever; no baseline characteristic was associated with its development. Median time to fever onset was 25.5 h (range, 9.5–100 h) and median peak temperature was 39.0 °C (range, 38.1–40.5 °C). Not a single patient developed hemodynamic or respiratory compromise that required admission to the intensive care unit. Fever was not explained by infection in any case. Ninety-one percent of the febrile episodes resolved within 96 h of cyclophosphamide administration. No significant difference in overall survival, event-free survival, or graft versus host disease-free/relapse-free survival was found in the group of febrile individuals after peripheral blood stem cell infusion. Conclusion: Fever after peripheral blood stem cell infusion in this clinical setting was common; it usually subsides with cyclophosphamide administration. The development of fever was not associated with an adverse prognosis.
Mención de responsabilidad :	Marcos Arango, Juan F Combariza
Referencia :	Hematol Oncol Stem Cell Ther. 2017 Jun;10(2):79-84.
DOI (Digital Object Identifier) :	10.1016/j.hemonc.2017.03.001
PMID :	28390959
En línea :	https://linkinghub.elsevier.com/retrieve/pii/S1658-3876(17)30031-6
Enlace permanente :	https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis